CDH1 and urothelial carcinoma: We chose to use pan-CK and VIM as biomarkers rather than E-cad and VIM (as done in some previous studies, see above), because a loss of E-cad expression has been reported as potentially being an early event in the progression of EMT [24,25], as we observed in the case of urothelial carcinomas (see Results).